Last reviewed · How we verify
ProTrans
At a glance
| Generic name | ProTrans |
|---|---|
| Also known as | Allogeneic transplantation with WJMSCs |
| Sponsor | NextCell Pharma Ab |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells (PHASE2)
- Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® (PHASE1)
- Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes (PHASE1, PHASE2)
- Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents (PHASE1, PHASE2)
- Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ProTrans CI brief — competitive landscape report
- ProTrans updates RSS · CI watch RSS
- NextCell Pharma Ab portfolio CI